US Patent 10,125,149 Scope and Claims for Palladium-Controlled API Compositions: What the Estate Covers, Key Claim Boundaries, and Generic Risk in the US
US Patent 10,125,149 is a US composition-of-matter patent directed to API compositions containing residual palladium at controlled levels, paired to specific salt/anion selections and two formula-defined drug substances (Formula (Va) and Formula (VII)). The enforceable scope is driven by three claim pillars: (i) inclusion of a compound of Formula (Va) or (VII), (ii) palladium content from 0.01 ppm up to a capped ceiling (1–5 ppm depending on claim), and (iii) for certain claims, restriction of the counterion A⊖ to listed pharmaceutically acceptable anions.
Executive snapshot
- Patent number: US 10,125,149
- Core claim type: composition containing controlled residual palladium
- Key quantitative boundary: 0.01 ppm to 5 ppm Pd (independent), with narrower dependent ceilings down to 1 ppm and an intermediate ladder (3 ppm, 2 ppm)
- Key qualitative boundary: A⊖ is limited to a fixed list when the claim recites anion selection
- Two covered drug substance identities: Formula (Va) and Formula (VII)
- Competitive relevance: residual Pd specifications can be met by alternative purification and manufacturing conditions; this patent targets product residual metal levels, not a dosing regimen
What does US 10,125,149 claim cover: palladium level-controlled compositions for Formula (Va) and Formula (VII)?
Direct answer: US 10,125,149 claims compositions that contain (a) an API of Formula (Va) or Formula (VII) and (b) residual palladium (Pd) within 0.01 to 5 ppm, with dependent claims narrowing the Pd ceiling and, in claim 1, limiting the counterion A⊖ to enumerated pharmaceutically acceptable anions.
Claim set structure
The claims provided break into two groups:
-
Formula (Va) group
- Claim 1 (independent): Formula (Va) composition with 0.01–5 ppm Pd; A⊖ selected from a defined list
- Claims 2–4 (dependent Pd ceilings): 0.01–3 ppm, 0.01–2 ppm, 0.01–1 ppm Pd respectively
- Claims 5–8 (dependent anions): A⊖ limited to specific anions: chloride, bisulfate, acetate, trifluoroacetate
-
Formula (VII) group
- Claim 9 (independent across Formula (VII)): Formula (VII) composition with 0.01–5 ppm Pd
- Claims 10–13 (dependent Pd ceilings): 0.01–3 ppm, 0.01–2 ppm, and 0.01–1 ppm, including claim 13 at 0.01–1 ppm
Practical interpretation of “composition comprising”
Because the claim uses “A composition comprising … and from about 0.01 ppm to about 5 ppm palladium,” the protected product is not limited to “only” those components. It is sufficient that the composition includes:
- the specified API substance (Formula (Va) or Formula (VII)), and
- residual Pd within the recited range, and
- if applicable, the specified anion/counterion definition.
This framing matters for formulation and excipients: excipients do not avoid infringement if the core conditions are met.
What are the independent claims in US 10,125,149 and what limits their scope?
Claim 1 (Formula (Va) + Pd range + defined anion list)
Essential elements
- Composition includes compound of Formula (Va)
- Contains palladium 0.01–5 ppm
- Counterion A⊖ is restricted to one of the listed pharmaceutically acceptable anions:
- chloride, bromide, iodide
- sulfate, bisulfate
- toluenesulfonate, methanesulfonate
- edisylate, maleate
- phosphate, ketoglutarate
- acetate, trifluoroacetate
- trifluoromethanesulfonate
Scope limiter: the anion list is an explicit gate for claim 1.
Claim 9 (Formula (VII) + Pd range; no explicit anion limitation in provided text)
Essential elements
- Composition includes compound of Formula (VII)
- Contains palladium 0.01–5 ppm
Scope limiter in provided claims: the claim text you provided does not add an anion list limitation for Formula (VII). The enforceable boundary is therefore the specific Formula (VII) identity plus the Pd range.
How strong are the Pd-threshold dependent claims (3 ppm, 2 ppm, 1 ppm) as a workaround risk?
The dependent claims set a ladder of Pd ceilings that can become decisive in infringement analysis because residual metal content can be measured by standard analytical methods and vary by batch.
- Claim 2: 0.01–3 ppm Pd (Formula (Va))
- Claim 3: 0.01–2 ppm Pd (Formula (Va))
- Claim 4: 0.01–1 ppm Pd (Formula (Va))
Parallel structure for Formula (VII):
- Claim 10: 0.01–3 ppm Pd (Formula (VII))
- Claim 11: 0.01–2 ppm Pd (Formula (VII))
- Claim 13: 0.01–1 ppm Pd (Formula (VII))
Key litigation-relevant boundary
A competitor can attempt to design around by targeting Pd outside the claimed range. The claims as provided run from 0.01 ppm up to about X ppm. A design-around often targets:
- below 0.01 ppm (if achievable and measurable), or
- above the ceiling (but this is often incompatible with regulatory specs or process goals)
Because “from about” is used, precision and measurement method become central for both validity/interpretation and infringement.
What anions are protected for Formula (Va): chloride, bisulfate, acetate, trifluoroacetate (and more) ?
Claim 1 anion enumeration (complete list in provided text)
When A⊖ is recited as an element of claim 1, protected anions include:
- Halides: chloride, bromide, iodide
- Sulfates: sulfate, bisulfate
- Sulfonates: toluene sulfonate, methanesulfonate
- Others: edisylate, maleate, phosphate, ketoglutarate
- Carboxylates/fluorinated acids: acetate, trifluoroacetate, trifluoromethanesulfonate
Dependent claims singling out specific anions
- Claim 5: A⊖ = chloride
- Claim 6: A⊖ = bisulfate
- Claim 7: A⊖ = acetate
- Claim 8: A⊖ = trifluoroacetate
How this affects generic strategy
If a competitor uses Formula (Va) but switches the counterion to a non-listed anion, they can attempt to avoid claim 1’s anion limitation. Whether such a switch avoids infringement in practice depends on whether:
- the competitor still meets the definition of “compound of Formula (Va)” as construed (salt vs free base depiction in the patent),
- the competitor’s anion is outside the enumerated list, and
- the remaining claim coverage (e.g., Pd ceilings) still matches.
For Formula (VII) claims 9–13, the provided claim text shows no anion list limitation, so a counterion switch is less likely to be a clean workaround for Formula (VII) coverage.
What patent-claim scope does US 10,125,149 provide over manufacturing process or only final product specifications?
Direct answer: Based on the claim language you supplied, the patent is directed to a final composition defined by identity of the compound and residual palladium level. It is not framed as a method claim in the excerpt.
Implication for freedom-to-operate
- Even if two manufacturing routes differ, infringement focuses on the residual Pd in the final API/composition meeting the claim thresholds.
- Process changes that reduce Pd content below the lowest claimed ceiling can avoid infringement, but “about 0.01 ppm” introduces measurement interpretation.
- If Pd varies batch-to-batch, a claim may still be infringed by batches that fall within the range.
Which later-stage product forms are likely covered: API, drug substance, or drug product?
From “composition comprising a compound of Formula (Va)/(VII),” US 10,125,149 likely covers:
- drug substance compositions (salt forms of the API) and/or
- drug product compositions if palladium content is present and the formula identity remains the claimed compound.
However, without the full specification and claim dependencies beyond what you pasted, the safest statement is that the claim is written broadly enough to cover any composition containing the claimed API and the required Pd range.
What design-arounds are available based on the palladium ranges (0.01–5 ppm; 3/2/1 ppm ceilings)?
Design-around targets
- Reduce residual Pd below 0.01 ppm
- If infeasible, exceed 5 ppm (usually commercially/regulatorily undesirable)
- For Formula (Va) salt forms, change A⊖ to a non-enumerated anion
- Use a distinct drug substance not captured by Formula (Va)/(VII) (requires chemical identity avoidance)
Most realistic approach
Given typical impurity control regimes, the most common competitive lever is process purification to reduce palladium. Whether that design actually avoids the patent depends on measurement method and whether batches land below the “about” threshold.
How does US 10,125,149 compare with typical residual-metal impurity patents in scope and enforceability?
Residual-metal patents often resemble this structure: claim the composition by residual metal content rather than the process. Compared with process-only claims, this structure:
- increases enforceability against any manufacturer producing the same product impurity profile
- increases litigation sensitivity to analytics and batch testing
In contrast, compared with broad method claims, this structure can be narrower if the accused products sit just outside the Pd range.
What generic entry risks exist for a Paragraph IV-style challenge based solely on this patent’s claim structure?
A challenger (or a generic applicant) typically evaluates:
- whether the generic’s API composition meets Pd 0.01–5 ppm (or narrower ceilings if applicable),
- whether the salt counterion matches the enumerated A⊖ list for claim 1, and
- whether the generic uses the same formula-defined drug substance identity (Va or VII).
A key point: if the generic product is engineered to show residual Pd below 0.01 ppm, it may argue non-infringement on claim boundary. If Pd overlaps the range, non-infringement arguments become harder because the claim is concentration-defined.
What Orange Book status and FDA exclusivity impact exist for US 10,125,149?
No Orange Book listing or FDA regulatory status is provided in your prompt. Without the NDA/BLA, listed product, and relevant Orange Book entry, no definitive status can be stated for this patent number.
What litigation or settlement posture affects practical enforcement of US 10,125,149?
No litigation docket, infringement action, or settlement date is provided in your prompt. Without case identifiers, no accurate litigation status can be stated.
What is the geographic enforceability of US 10,125,149?
US 10,125,149 is a US patent. It is enforceable in the United States (and only through cross-border mechanisms such as recognition procedures in other jurisdictions), with the infringement framework governed by US patent law and the FDA regime for pharmaceuticals in the US.
Key claim-to-competitive-product mapping: quick infringement checklist
Formula (Va) products
A product likely falls within claim 1 coverage if all are true:
- contains a compound of Formula (Va)
- has residual Pd between 0.01 and 5 ppm
- and the counterion is one of the enumerated A⊖ salts
If Pd is in the range but the counterion is outside the enumerated list, claim 1 may be avoided while other claims may still be assessed depending on how “compound of Formula (Va)” is construed in the full patent.
Formula (VII) products
A product likely falls within claims 9–13 coverage if:
- it contains a compound of Formula (VII)
- residual Pd is 0.01–5 ppm (claim 9) or within the narrower dependent ceilings (claims 10–13)
Key Takeaways
- US 10,125,149 protects a final composition profile defined by residual palladium levels paired to Formula (Va) and Formula (VII) APIs.
- Independent claim boundaries: Pd 0.01–5 ppm with an anion restriction for Formula (Va) in claim 1, and no anion list shown for Formula (VII) in claim 9 based on the provided claim text.
- Dependent claims create laddered Pd ceilings (3 ppm, 2 ppm, 1 ppm) that increase precision in infringement and design-around assessments.
- For Formula (Va), salt selection can matter because A⊖ is enumerated; for Formula (VII), Pd thresholds are the dominant apparent lever.
- Competition risk is analytically driven: infringement turns on measured residual Pd and on whether the accused API matches Formula (Va) or (VII).
FAQs
1. If a generic product has residual palladium slightly above 5 ppm, does US 10,125,149 still risk infringement?
Not on claim 1/9 as written, because the claims define Pd up to “about 5 ppm” and “about” language can still cover values near the boundary depending on construction and measurement.
2. Can changing the counterion avoid infringement for both Formula (Va) and Formula (VII) claims?
Counterion change is a potential avoidance lever for the Formula (Va) anion-restricted claim 1, but based on the provided text it is not a parallel lever for Formula (VII) claims 9–13.
3. Does “composition comprising” allow excipients and still infringe US 10,125,149?
Yes. The “comprising” transition generally allows additional components as long as the claimed composition elements (compound identity, Pd range, and required salt identity where recited) are present.
4. Are US 10,125,149’s dependent palladium-range claims mutually exclusive or cumulative?
They are dependent and narrow. If a composition meets a narrower ceiling, it also lies within the broader Pd range element of the independent claim in normal concentration arithmetic, subject to claim construction of “about.”
5. What is the practical strongest claim for enforcement among the provided claims?
The strongest practical handle is typically independent claim 1 for Formula (Va) or independent claim 9 for Formula (VII) because they define the full Pd range. Dependent claims can still be asserted as narrower fallback positions.
References
- United States Patent US 10,125,149, “Palladium content controlled compositions comprising compounds of Formula (Va) and Formula (VII)” (claims excerpt as provided).
